Effects of postoperative radiotherapy on leptomeningeal carcinomatosis or dural metastasis after resection of brain metastases in breast cancer patients

Boram Ha, Seung Yeun Chung, Yeon Joo Kim, Ho Shin Gwak, Jong Hee Chang, Sang Hyun Lee, In Hae Park, Keun Seok Lee, Seeyoun Lee, Tae Hyun Kim, Dae Yong Kim, Seok Gu Kang, Chang Ok Suh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose In this retrospective study, we compared the incidence of leptomeningeal carcinomatosis or dural metastasis (LMCDM) in patients who received whole brain radiotherapy (WBRT), partial radiotherapy (PRT), or no radiotherapy (RT) following resection of brain metastases from breast cancer. Materials and Methods Fifty-one patients with breast cancer underwent surgical resection for newly diagnosed brain metastases in two institutions between March 2001 and March 2015. Among these, 34 received postoperative WBRT (n=24) or PRT (n=10) and 17 did not. Results With a median follow-up of 12.4 months (range, 2.3 to 83.6 months), 22/51 patients developed LMCDM at a median of 8.6 months (range, 4.8 to 51.2 months) after surgery. The 18-months LMCDM-free survival (LMCDM-FS) rates were 77.5%, 30.0%, and 13.6%, in the WBRT, PRT, and no RT groups, respectively (p=0.013). The presence of a tumor adjacent to cerebrospinal fluid flow and no systemic treatment after treatment for brain metastases were also associated with poor LMCDM-FS rate. Multivariate analysis showed that WBRT compared to PRT (p=0.009) and systemic treatment (p < 0.001) were independently associated with reduced incidence of LMCDM. Conclusion WBRT improved LMCDM-FS rate after resection of brain metastases compared to PRT in breast cancer patients.

Original languageEnglish
Pages (from-to)748-758
Number of pages11
JournalCancer Research and Treatment
Volume49
Issue number3
DOIs
Publication statusPublished - 2017 Jul 1

Fingerprint

Meningeal Carcinomatosis
Radiotherapy
Breast Neoplasms
Neoplasm Metastasis
Brain
Incidence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Ha, Boram ; Chung, Seung Yeun ; Kim, Yeon Joo ; Gwak, Ho Shin ; Chang, Jong Hee ; Lee, Sang Hyun ; Park, In Hae ; Lee, Keun Seok ; Lee, Seeyoun ; Kim, Tae Hyun ; Kim, Dae Yong ; Kang, Seok Gu ; Suh, Chang Ok. / Effects of postoperative radiotherapy on leptomeningeal carcinomatosis or dural metastasis after resection of brain metastases in breast cancer patients. In: Cancer Research and Treatment. 2017 ; Vol. 49, No. 3. pp. 748-758.
@article{9e273baadd6c4a4d95fefe330b9fdafe,
title = "Effects of postoperative radiotherapy on leptomeningeal carcinomatosis or dural metastasis after resection of brain metastases in breast cancer patients",
abstract = "Purpose In this retrospective study, we compared the incidence of leptomeningeal carcinomatosis or dural metastasis (LMCDM) in patients who received whole brain radiotherapy (WBRT), partial radiotherapy (PRT), or no radiotherapy (RT) following resection of brain metastases from breast cancer. Materials and Methods Fifty-one patients with breast cancer underwent surgical resection for newly diagnosed brain metastases in two institutions between March 2001 and March 2015. Among these, 34 received postoperative WBRT (n=24) or PRT (n=10) and 17 did not. Results With a median follow-up of 12.4 months (range, 2.3 to 83.6 months), 22/51 patients developed LMCDM at a median of 8.6 months (range, 4.8 to 51.2 months) after surgery. The 18-months LMCDM-free survival (LMCDM-FS) rates were 77.5{\%}, 30.0{\%}, and 13.6{\%}, in the WBRT, PRT, and no RT groups, respectively (p=0.013). The presence of a tumor adjacent to cerebrospinal fluid flow and no systemic treatment after treatment for brain metastases were also associated with poor LMCDM-FS rate. Multivariate analysis showed that WBRT compared to PRT (p=0.009) and systemic treatment (p < 0.001) were independently associated with reduced incidence of LMCDM. Conclusion WBRT improved LMCDM-FS rate after resection of brain metastases compared to PRT in breast cancer patients.",
author = "Boram Ha and Chung, {Seung Yeun} and Kim, {Yeon Joo} and Gwak, {Ho Shin} and Chang, {Jong Hee} and Lee, {Sang Hyun} and Park, {In Hae} and Lee, {Keun Seok} and Seeyoun Lee and Kim, {Tae Hyun} and Kim, {Dae Yong} and Kang, {Seok Gu} and Suh, {Chang Ok}",
year = "2017",
month = "7",
day = "1",
doi = "10.4143/crt.2016.303",
language = "English",
volume = "49",
pages = "748--758",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Cancer Association",
number = "3",

}

Effects of postoperative radiotherapy on leptomeningeal carcinomatosis or dural metastasis after resection of brain metastases in breast cancer patients. / Ha, Boram; Chung, Seung Yeun; Kim, Yeon Joo; Gwak, Ho Shin; Chang, Jong Hee; Lee, Sang Hyun; Park, In Hae; Lee, Keun Seok; Lee, Seeyoun; Kim, Tae Hyun; Kim, Dae Yong; Kang, Seok Gu; Suh, Chang Ok.

In: Cancer Research and Treatment, Vol. 49, No. 3, 01.07.2017, p. 748-758.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of postoperative radiotherapy on leptomeningeal carcinomatosis or dural metastasis after resection of brain metastases in breast cancer patients

AU - Ha, Boram

AU - Chung, Seung Yeun

AU - Kim, Yeon Joo

AU - Gwak, Ho Shin

AU - Chang, Jong Hee

AU - Lee, Sang Hyun

AU - Park, In Hae

AU - Lee, Keun Seok

AU - Lee, Seeyoun

AU - Kim, Tae Hyun

AU - Kim, Dae Yong

AU - Kang, Seok Gu

AU - Suh, Chang Ok

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Purpose In this retrospective study, we compared the incidence of leptomeningeal carcinomatosis or dural metastasis (LMCDM) in patients who received whole brain radiotherapy (WBRT), partial radiotherapy (PRT), or no radiotherapy (RT) following resection of brain metastases from breast cancer. Materials and Methods Fifty-one patients with breast cancer underwent surgical resection for newly diagnosed brain metastases in two institutions between March 2001 and March 2015. Among these, 34 received postoperative WBRT (n=24) or PRT (n=10) and 17 did not. Results With a median follow-up of 12.4 months (range, 2.3 to 83.6 months), 22/51 patients developed LMCDM at a median of 8.6 months (range, 4.8 to 51.2 months) after surgery. The 18-months LMCDM-free survival (LMCDM-FS) rates were 77.5%, 30.0%, and 13.6%, in the WBRT, PRT, and no RT groups, respectively (p=0.013). The presence of a tumor adjacent to cerebrospinal fluid flow and no systemic treatment after treatment for brain metastases were also associated with poor LMCDM-FS rate. Multivariate analysis showed that WBRT compared to PRT (p=0.009) and systemic treatment (p < 0.001) were independently associated with reduced incidence of LMCDM. Conclusion WBRT improved LMCDM-FS rate after resection of brain metastases compared to PRT in breast cancer patients.

AB - Purpose In this retrospective study, we compared the incidence of leptomeningeal carcinomatosis or dural metastasis (LMCDM) in patients who received whole brain radiotherapy (WBRT), partial radiotherapy (PRT), or no radiotherapy (RT) following resection of brain metastases from breast cancer. Materials and Methods Fifty-one patients with breast cancer underwent surgical resection for newly diagnosed brain metastases in two institutions between March 2001 and March 2015. Among these, 34 received postoperative WBRT (n=24) or PRT (n=10) and 17 did not. Results With a median follow-up of 12.4 months (range, 2.3 to 83.6 months), 22/51 patients developed LMCDM at a median of 8.6 months (range, 4.8 to 51.2 months) after surgery. The 18-months LMCDM-free survival (LMCDM-FS) rates were 77.5%, 30.0%, and 13.6%, in the WBRT, PRT, and no RT groups, respectively (p=0.013). The presence of a tumor adjacent to cerebrospinal fluid flow and no systemic treatment after treatment for brain metastases were also associated with poor LMCDM-FS rate. Multivariate analysis showed that WBRT compared to PRT (p=0.009) and systemic treatment (p < 0.001) were independently associated with reduced incidence of LMCDM. Conclusion WBRT improved LMCDM-FS rate after resection of brain metastases compared to PRT in breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85021979816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021979816&partnerID=8YFLogxK

U2 - 10.4143/crt.2016.303

DO - 10.4143/crt.2016.303

M3 - Article

C2 - 27809457

AN - SCOPUS:85021979816

VL - 49

SP - 748

EP - 758

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 3

ER -